Rallybio Holdings LLC (RLYB) News

Form 8-K - Current report

Rallybio to Discontinue Development of RLYB212 for Prevention of FNAIT

– RLYB212 Phase 2 PK Results Did Not Achieve Target Concentrations, Including Minimum Target Concentration Required for Efficacy – – RLYB116...

Form DEF 14A - Other definitive proxy statements

Form 8-K - Current report

Form 424B5 - Prospectus [Rule 424(b)(5)]

Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]

Form 8-K - Current report

Form 8-K - Current report

Rallybio to Present at the TD Cowen 45th Annual Health Care Conference

Rallybio Corporation (Nasdaq: RLYB), a clinical-stage biotechnology company translating scientific advances into transformative therapies for...

Form 4 - Statement of changes in beneficial ownership of securities

Form SCHEDULE 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]

Rallybio Announces Initiation of Dosing in RLYB212 Phase 2 Clinical Trial

– Key Data Readouts from Sentinel Participant Expected in 2Q 2025 and 3Q 2025 – Rallybio Corporation (Nasdaq: RLYB), a clinical-stage...

Rallybio Highlights 2024 Accomplishments and Anticipated Milestones for 2025

– Dosing of Sentinel (First) Participant in RLYB212 Phase 2 Clinical Trial Expected in 2Q 2025 – – Initiation of RLYB116 Confirmatory PK/PD Study...

Form 4 - Statement of changes in beneficial ownership of securities

Rallybio Announces Promising RLYB212 and RLYB332 Preclinical Data at the 66th American Society of Hematology Annual Meeting

Rallybio Corporation (Nasdaq: RLYB), a clinical-stage biotechnology company translating scientific advances into transformative therapies for...